SI3077396T1 - Sinteza trans-8-kloro-5-metil-1-(4-(piridin-2-iloksi)-cikloheksil)-5,6- dihidro-4H-2,3,5,10b-tetraaza-benzo(e)azulena in njegovih kristalnih oblik - Google Patents
Sinteza trans-8-kloro-5-metil-1-(4-(piridin-2-iloksi)-cikloheksil)-5,6- dihidro-4H-2,3,5,10b-tetraaza-benzo(e)azulena in njegovih kristalnih oblikInfo
- Publication number
- SI3077396T1 SI3077396T1 SI201431838T SI201431838T SI3077396T1 SI 3077396 T1 SI3077396 T1 SI 3077396T1 SI 201431838 T SI201431838 T SI 201431838T SI 201431838 T SI201431838 T SI 201431838T SI 3077396 T1 SI3077396 T1 SI 3077396T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tetraaza
- azulene
- yloxy
- pyridin
- benzo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195864 | 2013-12-05 | ||
| EP14805290.5A EP3077396B1 (en) | 2013-12-05 | 2014-12-01 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof |
| PCT/EP2014/076041 WO2015082370A1 (en) | 2013-12-05 | 2014-12-01 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3077396T1 true SI3077396T1 (sl) | 2021-08-31 |
Family
ID=49726573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431838T SI3077396T1 (sl) | 2013-12-05 | 2014-12-01 | Sinteza trans-8-kloro-5-metil-1-(4-(piridin-2-iloksi)-cikloheksil)-5,6- dihidro-4H-2,3,5,10b-tetraaza-benzo(e)azulena in njegovih kristalnih oblik |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10246460B2 (enExample) |
| EP (1) | EP3077396B1 (enExample) |
| JP (1) | JP6454707B2 (enExample) |
| KR (3) | KR102384630B1 (enExample) |
| CN (1) | CN105793263B (enExample) |
| AR (1) | AR098592A1 (enExample) |
| AU (2) | AU2014359409A1 (enExample) |
| CA (2) | CA2931016C (enExample) |
| ES (1) | ES2875411T3 (enExample) |
| HR (1) | HRP20210966T1 (enExample) |
| IL (2) | IL245450A0 (enExample) |
| MX (1) | MX372971B (enExample) |
| MY (1) | MY175464A (enExample) |
| NZ (1) | NZ720340A (enExample) |
| PL (1) | PL3077396T3 (enExample) |
| SG (1) | SG11201604502SA (enExample) |
| SI (1) | SI3077396T1 (enExample) |
| WO (1) | WO2015082370A1 (enExample) |
| ZA (1) | ZA201603304B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102384630B1 (ko) * | 2013-12-05 | 2022-04-11 | 에프. 호프만-라 로슈 아게 | 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성 |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| JP7308193B2 (ja) | 2017-12-08 | 2023-07-13 | エフ． ホフマン－ラ ロシュ アーゲー | 医薬組成物 |
| WO2020139670A1 (en) | 2018-12-27 | 2020-07-02 | Teva Pharmaceuticals International Gmbh | Solid state forms of balovaptan |
| KR20230049576A (ko) | 2021-10-06 | 2023-04-13 | 주식회사 엘지에너지솔루션 | 배터리 모듈 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1197242A (en) * | 1983-03-02 | 1985-11-26 | Jean A. Gauthier | Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| DE602004003914T2 (de) * | 2003-02-19 | 2007-05-31 | Pfizer Inc. | Für die therapie geeignete triazolverbindungen |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| JP2008510789A (ja) | 2004-08-25 | 2008-04-10 | ファイザー・インク | トリアゾロベンゾジアゼピン及びバゾプレシンアンタゴニストとしてのそれらの使用 |
| US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| DK2358714T3 (da) * | 2008-11-18 | 2012-08-20 | Hoffmann La Roche | Alkylcyclohexylethere af dihydrotetraazabenzoazulener |
| KR101359742B1 (ko) * | 2008-11-28 | 2014-02-06 | 에프. 호프만-라 로슈 아게 | 수용체 길항제를 통해 바소프레신으로 사용되는 다이하이드로테트라아자벤조아줄렌의 아릴사이클로헥실에테르 |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| EP3035939B1 (en) | 2013-08-19 | 2020-03-25 | F. Hoffmann-La Roche AG | V1a antagonists to treat phase shift sleep disorders |
| KR102384630B1 (ko) | 2013-12-05 | 2022-04-11 | 에프. 호프만-라 로슈 아게 | 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성 |
-
2014
- 2014-12-01 KR KR1020217034765A patent/KR102384630B1/ko active Active
- 2014-12-01 CN CN201480065960.4A patent/CN105793263B/zh active Active
- 2014-12-01 NZ NZ720340A patent/NZ720340A/en unknown
- 2014-12-01 ES ES14805290T patent/ES2875411T3/es active Active
- 2014-12-01 KR KR1020217034768A patent/KR102384629B1/ko active Active
- 2014-12-01 CA CA2931016A patent/CA2931016C/en active Active
- 2014-12-01 PL PL14805290T patent/PL3077396T3/pl unknown
- 2014-12-01 AU AU2014359409A patent/AU2014359409A1/en not_active Abandoned
- 2014-12-01 WO PCT/EP2014/076041 patent/WO2015082370A1/en not_active Ceased
- 2014-12-01 SG SG11201604502SA patent/SG11201604502SA/en unknown
- 2014-12-01 HR HRP20210966TT patent/HRP20210966T1/hr unknown
- 2014-12-01 CA CA3142754A patent/CA3142754C/en active Active
- 2014-12-01 EP EP14805290.5A patent/EP3077396B1/en active Active
- 2014-12-01 KR KR1020167017925A patent/KR102384608B1/ko active Active
- 2014-12-01 JP JP2016536746A patent/JP6454707B2/ja active Active
- 2014-12-01 SI SI201431838T patent/SI3077396T1/sl unknown
- 2014-12-01 MY MYPI2016000870A patent/MY175464A/en unknown
- 2014-12-01 MX MX2016006558A patent/MX372971B/es active IP Right Grant
- 2014-12-03 AR ARP140104488A patent/AR098592A1/es unknown
-
2016
- 2016-05-03 IL IL245450A patent/IL245450A0/en unknown
- 2016-05-16 ZA ZA2016/03304A patent/ZA201603304B/en unknown
- 2016-06-03 US US15/172,542 patent/US10246460B2/en active Active
-
2019
- 2019-02-18 IL IL264891A patent/IL264891B/en active IP Right Grant
- 2019-02-20 AU AU2019201183A patent/AU2019201183B2/en active Active
- 2019-03-04 US US16/291,887 patent/US11040977B2/en active Active
-
2021
- 2021-06-03 US US17/337,547 patent/US12459947B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3062825A4 (en) | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | |
| EP3076918A4 (en) | Liposomal particles, methods of making same and uses thereof | |
| EP3065776A4 (en) | Novel anti-claudin antibodies and methods of use | |
| EP3047523A4 (en) | High voltage mosfet devices and methods of making the devices | |
| EP3074377A4 (en) | Substituted benzamides and methods of use thereof | |
| EP3079719B8 (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| EP3080607A4 (en) | Novel anti-dpep3 antibodies and methods of use | |
| EP3089989A4 (en) | Cas9 crystals and methods of use thereof | |
| EP3053910A4 (en) | Aniline derivatives and uses thereof | |
| EP3046932A4 (en) | Evolved sortases and uses thereof | |
| PT2893004T (pt) | Recetor de antígeno quimérico de cadeia múltipla e utilizações do mesmo | |
| EP3055310A4 (en) | Deubiquitinase inhibitors and methods for use of the same | |
| HUE044285T2 (hu) | PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése | |
| EP2967354A4 (en) | Multi-modal pharmaco-diagnostic assessment of brian helath | |
| IL264891B (en) | Preparation of trans-8-chloro-5-methyl-1-[4-(pyridine-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5b,10-tetrahaza-benzo[e] Azulane and its crystalline forms | |
| EP3060705A4 (en) | Insulating materials and methods of forming same | |
| EP3052525A4 (en) | Anti-epcam antibodies and methods of use | |
| WO2014147640A3 (en) | Process for the preparation of anagliptin | |
| EP3027182A4 (en) | Novel copper-cysteamine and methods of use | |
| EP3008072A4 (en) | Synthesis of isohexide dicarbamates and derivatives thereof | |
| EP3041863A4 (en) | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles | |
| EP3030516A4 (en) | SYNTHESIS OF CORE CASE METAL SEMICONDUCTOR NANOMATERIALS | |
| EP3043790A4 (en) | Novel anthranilic amides and the use thereof | |
| EP3055307A4 (en) | Substituted berbines and their synthesis | |
| EP3044321A4 (en) | New marker for the classification, diagnosis and treatment of scoliosis |